Bimekizumab significantly improved psoriasis symptoms and health-related quality of life within 4 weeks and sustained benefits through 3 years.
2
In a phase IIIb trial, 743 patients with moderate to severe plaque psoriasis were randomized to receive either bimekizumab or secukinumab.
3
At year 3, 62.2% of continuous bimekizumab patients achieved both PASI score of 0 and DLQI score of 0 or 1, compared to 63.8% of those who switched from secukinumab.
4
Patient-reported outcomes showed higher rates of symptom absence and quality of life improvement in the bimekizumab group compared to the secukinumab group.
5
The study's strengths included a large sample size and low dropout rate, while limitations involved potential biases and restricted generalizability.
Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.
